Advanced NanoTherapies
- Company typePrivate
- Founded2020
- HeadquartersLos Gatos, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Advanced NanoTherapies firmographics
Firmographics- Name
- Advanced NanoTherapies
- Legal name
- Advanced NanoTherapies, Inc.
- Website
- https://advnanot.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Advanced NanoTherapies industry classification
Industry- Product category
- Drug-Coated Balloons / Cardiovascular Medical Devices
- NAICS
- Medical Equipment and Supplies Manufacturing (3391), Research and Development in Nanotechnology (541713)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Peripheral Vascular Intervention (PAD Stents, Balloons, Atherectomy) (HLAHAFAE)
- akta.pro secondary industry
- Connected Therapeutics & Smart Drug Delivery Monitoring (HLACAFAL)
Keywords
Where Advanced NanoTherapies is headquartered
LocationHeadquarters
- HQ city
- Los Gatos
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Advanced NanoTherapies business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
Revenue model
- Medical Device Sales (Future): Once FDA approved, the company plans to commercialize the SirPlux Duo drug-coated balloon through direct hospital/cath lab sales. Products are currently in development and not available for sale.
- Licensing Royalties (Potential): The drug-agnostic nanoparticle platform could generate licensing revenue from partnerships with other medical device companies seeking drug delivery solutions.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels4 records
Advanced NanoTherapies product offering
Product offeringCore offering
Advanced NanoTherapies develops the SirPlux Duo Drug Coated Balloon (DCB), a next-generation medical device that simultaneously delivers Sirolimus and Paclitaxel via proprietary biodegradable functionalized nanoparticles for treating coronary artery disease (CAD) and peripheral artery disease (PAD). The platform is exclusively licensed from Cleveland Clinic and provides sustained drug release and retention at lesion sites without leaving a permanent implant. The product is currently in clinical development and not yet available for sale, with FDA Breakthrough Device Designation granted for below-the-knee (BTK) peripheral applications.
Product overview
Advanced NanoTherapies offers a single unified product: the SirPlux™ Duo Drug Coated Balloon (DCB), a nanoparticle-based dual-drug delivery platform. The platform is designed to deliver Sirolimus and Paclitaxel simultaneously through functionalized nanoparticles, providing higher potency and lower dosage compared to single-drug alternatives. The technology is exclusively licensed from Cleveland Clinic and is drug-agnostic, meaning the same excipient formulation can theoretically be used with other drug combinations. The product is currently in clinical development for coronary and peripheral artery disease applications, with FDA Breakthrough Device designation for below-the-knee (BTK) peripheral applications.
Differentiator
Problem solved
Functional benefit
Brands
- SirPlux Duo: Dual-drug nanoparticle-coated balloon platform for treating coronary and peripheral artery disease, combining paclitaxel and sirolimus
Products and services
- SirPlux Duo Drug Coated Balloon (DCB) A next-generation drug-coated balloon that simultaneously delivers Sirolimus and Paclitaxel via a proprietary nanoparticle drug delivery platform for treating coronary artery disease (CAD) and peripheral artery disease (PAD), including below-the-knee (BTK) applications. The product provides sustained drug release and retention at the lesion site without leaving a permanent implant, and has received FDA Breakthrough Device Designation for BTK use. Currently in clinical development and not available for sale.
Quantifiable outcome
- No new treatment failures over two years of follow-up in 28-patient first-in-human study
- +2 more outcomes
Companies that use Advanced NanoTherapies
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles1 record
Advanced NanoTherapies technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Advanced NanoTherapies partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Cleveland CliniccoreExclusive license agreement for proprietary nanoparticle technology enabling dual-drug delivery (paclitaxel and sirolimus) in vascular treatment applications. This is the foundational technology underlying the SirPlux Duo platform.
Scale indicators6 records
Recent moves6 records
Expansion highlights5 records
Advanced NanoTherapies competitors and assessment
Company assessmentMarket position
Competitive moat3 records
Key highlights6 records
Customer concentration
Advanced NanoTherapies social profiles
Digital presenceAdvanced NanoTherapies financial estimates
Financial estimateRevenue estimate
Valuation estimate
Advanced NanoTherapies leadership team
Management profileNumber of profiles
Profiles3 records
Advanced NanoTherapies funding detail
Funding detailFunding overview
Funding rounds4 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Advanced NanoTherapies M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Advanced NanoTherapies
What does Advanced NanoTherapies do?
Advanced NanoTherapies develops the SirPlux Duo Drug Coated Balloon (DCB), a next-generation medical device that simultaneously delivers Sirolimus and Paclitaxel via proprietary biodegradable functionalized nanoparticles for treating coronary artery disease (CAD) and peripheral artery disease (PAD). The platform is exclusively licensed from Cleveland Clinic and provides sustained drug release and retention at lesion sites without leaving a permanent implant. The product is currently in clinical development and not yet available for sale, with FDA Breakthrough Device Designation granted for below-the-knee (BTK) peripheral applications.
Is Advanced NanoTherapies a public or private company?
Advanced NanoTherapies is a private company. It is classified as venture growth investor backed and is currently operating.
When was Advanced NanoTherapies founded?
Advanced NanoTherapies was founded in 2020. It employs 11 to 50 people.
Where is Advanced NanoTherapies based?
Advanced NanoTherapies is headquartered in Los Gatos, United States, in the North America region.
How does Advanced NanoTherapies make money?
Two revenue lines are on record. Medical Device Sales (Future) is the primary driver. The others are licensing Royalties (Potential).
Does Advanced NanoTherapies have an API?
No public API is recorded for Advanced NanoTherapies.
What industry is Advanced NanoTherapies in?
Advanced NanoTherapies's product category is Drug-Coated Balloons / Cardiovascular Medical Devices. Its primary akta.pro industry code is HLAHAFAE, Peripheral Vascular Intervention (PAD Stents, Balloons, Atherectomy), with a secondary code of HLACAFAL, Connected Therapeutics & Smart Drug Delivery Monitoring. Its NAICS code is 3391 and its SIC code is 3841.